Dr. Matthew Zirwas breaks down recent updates in dermatology literature presented during his conference session. He notes some of the least painful injectable biologics for atopic dermatitis and psoriasis, respectively. Furthermore, managing dupilumab treatment failure depends on whether the response is primary or secondary, favoring a switch to a JAK inhibitor for primary failures and an alternative IL-13 inhibitor for secondary failures. Finally, he explains the dual-pathway mechanism behind JAK inhibitor clot risks in rheumatoid arthritis and clarifies that dupilumab unmasks early cryptic cutaneous T-cell lymphoma rather than causing it.
